Despite recent technological advances, novel allergen discovery is limited by the low abundance of particular allergenic proteins, the large diversity of allergen sources, and the high variability in patient IgE antibody reactivity due to study specific populations. Here we describe a comprehensive discovery pipeline for allergenic proteins that accounts for biological and molecular variability using allergenomics, high-throughput screening of genomic databases and high-resolution mass spectrometry.